Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.
about
Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.Haematopoietic stem cell transplantation for autoimmune diseases.Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsyA phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune diseaseHaematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow TransplantationCardiac and cardiovascular consequences after haematopoietic stem cell transplantation.Treatment of systemic sclerosis: potential role for stem cell transplantation.Hematopoietic stem cell transplantation for systemic lupus erythematosus, the antiphospholipid syndrome and bullous skin diseases.Autologous stem cell transplantation for systemic sclerosis.Cardiac complications of systemic sclerosis.Autologous hematopoietic stem cell transplantation in autoimmune diseases.Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases.An update on stem cell transplantation in autoimmune rheumatologic disorders.Feasibility of cell therapy in multiple sclerosis: a systematic review of 83 studies.Stem cell therapies for systemic sclerosis.Stem cell autograft and allograft in autoimmune diseases.Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis.Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners.Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?Natalizumab: Increased Vigilance is Required in Treating Patients with Multiple Sclerosis.Resolution of sclerodermatous myocarditis after autologous stem cell transplantation.Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations.Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic SclerosisSystemic sclerosis: state of the art on clinical practice guidelines
P2860
Q33632260-51D3B1A6-72E3-4920-85A0-E9F4DFEB96EFQ34551863-497122D8-4B2C-44A5-87E7-4848CB61ACA7Q35597574-A54E347F-E4E9-4C77-A9F9-A6C7801AB165Q35636989-9A5748DF-654F-44CB-A608-6C8AFBF56E17Q36020897-1F539F3E-F947-404A-ACDC-46D45AE8DE1DQ37145279-0995667C-E35F-4E9E-BC65-45718D2E5066Q37194001-420A2889-7B5D-4976-ADE5-8D2DEA398D34Q37311073-CCDEE325-E026-4289-85C8-406C6B015B27Q37311078-13E0C1AF-9EBB-4913-B0D3-9111240CC61EQ37504315-9010EF72-3E33-4EEF-A556-DFB7B5857A11Q37810087-7140E00B-A842-410D-A140-9751199E119FQ37995011-1AE4F764-0787-4CA9-B27A-E7BD4A8D4C90Q38041499-5A6F71D9-F227-4389-8245-05D8B99BCB34Q38186029-232A247E-0ACF-4385-9E47-FBC892DA937BQ38265814-609B053B-164A-4549-847B-0EA9BCE6D73AQ38287103-85FAC984-3938-4479-9A79-32469203D524Q38466458-4C52498F-BD5C-45D7-BDC6-B266A6551C26Q38750270-616B4EC7-4029-46CC-AB89-7C07CBADCB45Q39322066-0055E3D0-A53E-40E5-B118-8531C65A9112Q40237552-BDF0ADFC-2C73-4A7E-A89D-ED6B060332D8Q41173457-78814A60-C8CB-4644-99D5-6125FEC22EC6Q42955660-08A76A8C-7666-4E6E-9B69-FE6F53D03078Q51166044-2A78D57F-54DE-4FDF-A7B2-CE8F78D98B2DQ58553753-1C34CC2B-10B9-4C7E-9E34-01F31AAD3B7EQ58602910-628F583A-A9F5-4BFE-B186-7AA1E7F15082
P2860
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Consensus statement concerning ...... erosis and multiple sclerosis.
@ast
Consensus statement concerning ...... erosis and multiple sclerosis.
@en
type
label
Consensus statement concerning ...... erosis and multiple sclerosis.
@ast
Consensus statement concerning ...... erosis and multiple sclerosis.
@en
prefLabel
Consensus statement concerning ...... erosis and multiple sclerosis.
@ast
Consensus statement concerning ...... erosis and multiple sclerosis.
@en
P2093
P2860
P356
P1476
Consensus statement concerning ...... erosis and multiple sclerosis.
@en
P2093
Bocelli-Tyndall C
P2860
P2888
P304
P356
10.1038/SJ.BMT.1704656
P407
P577
2004-11-01T00:00:00Z